{"disease":{"id":"neoadjuvant-therapy","name":"neoadjuvant therapy"},"drugs":{"marketed":[{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with axitinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with lenvatinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with pembrolizumab and lenvatinib.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with pembrolizumab and lenvatinib in patients with a PD-L1 CPS ≥ 10 as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07203690","title":"Development and Application of AI-Based Therapeutic Strategies for Esophageal Cancer Integrating Multimodal Imaging and Digital Pathology","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT05906407","title":"COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"German Cancer Research Center","has_results":false},{"nct_id":"NCT05617469","title":"DLCS for Predicting Neoadjuvant Chemotherapy Response","phase":"","overall_status":"UNKNOWN","enrollment_count":1100,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT06385912","title":"Systematic Lymphadenectomy During Interval Debulking Surgery in Advanced Epithelial Ovarian Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1090,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT03437837","title":"Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China","phase":"","overall_status":"COMPLETED","enrollment_count":1077,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT06149884","title":"Micrometastases in Axillary Lymph Nodes in Breast Cancer, Post-neoadjuvant Chemotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":978,"lead_sponsor_name":"Gangnam Severance Hospital","has_results":false},{"nct_id":"NCT04717947","title":"Interval Between Neoadjuvant Therapy and Surgery in the Treatment of Locally Advanced Rectal Cancer (CRONOS)","phase":"","overall_status":"UNKNOWN","enrollment_count":911,"lead_sponsor_name":"Hospital Clinic of Barcelona","has_results":false},{"nct_id":"NCT05406999","title":"Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT05953181","title":"Statistical Analysis Plan for the SANO-trial: Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Active Surveillance for Oesophageal Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":776,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT06755567","title":"Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":750,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06925243","title":"Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":682,"lead_sponsor_name":"Zuoyi Jiao","has_results":false},{"nct_id":"NCT06949033","title":"Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":668,"lead_sponsor_name":"Zuoyi Jiao","has_results":false},{"nct_id":"NCT03493880","title":"The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06689462","title":"Appraisal of the Modified Cancer Cachexia Index in Locally Advanced Gastric Cancer Patients Undergoing Neoadjuvant Chemotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT04004559","title":"MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02)","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT04922853","title":"Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":554,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06909643","title":"Development and Prospective Validation of a Multimodal Fusion Artificial Intelligence Model for Predicting the Efficacy of Neoadjuvant Treatment of Bladder Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":550,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT04486495","title":"Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":549,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT06908291","title":"Photoacoustic/Ultrasound Imaging for Breast Nodule Diagnosis, Molecular Classification, and Neoadjuvant Chemotherapy Response Evaluation","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06926179","title":"Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT03592004","title":"Radiomics of Mp-MRI Assessing NAC Outcome in Breast Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Chinese Academy of Sciences","has_results":false},{"nct_id":"NCT06734702","title":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":497,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06497660","title":"Effect of Neoadjuvant Chemotherapy on Cardiac Function of Perioperative Patients With Breast Cancer and New Strategies for Anesthesia","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":496,"lead_sponsor_name":"Fujian Medical University Union Hospital","has_results":false},{"nct_id":"NCT07051083","title":"Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale","phase":"","overall_status":"RECRUITING","enrollment_count":480,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06326619","title":"Survival Benefit of Primary Tumour Resection Compared to Systemic Therapy Alone in Stage IV Colorectal Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":480,"lead_sponsor_name":"Medizinische Hochschule Brandenburg Theodor Fontane","has_results":false},{"nct_id":"NCT06120309","title":"New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":465,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06704945","title":"No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":464,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT06630481","title":"Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade","phase":"","overall_status":"COMPLETED","enrollment_count":462,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT03177382","title":"Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":458,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06288373","title":"Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":440,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT07113275","title":"A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":435,"lead_sponsor_name":"Tao Zhang","has_results":false},{"nct_id":"NCT06714604","title":"Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":432,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT06958432","title":"Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":430,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT06938906","title":"Multimodal Therapy Impact on Pancreatic Cancer Survival","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":405,"lead_sponsor_name":"National Cheng Kung University","has_results":false},{"nct_id":"NCT06913777","title":"Neoadjuvant SNF Precision Therapy Phase III","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":404,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06904677","title":"Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04028375","title":"Study of CT and MR in the Gastric Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT06758830","title":"Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos","has_results":false},{"nct_id":"NCT07135856","title":"Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT07373899","title":"Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":354,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04932460","title":"Contrast-enhanced Ultrasonography Combined With Blue Dye as Dual-tracer for Sentinel Lymph Node Biopsy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":350,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06212440","title":"Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":348,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT03750669","title":"Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":324,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07509632","title":"Predicting Pathological Complete Response in Rectal Cancer Using Machine Learning","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":320,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05901779","title":"Effect of Probiotic Supplements on Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":318,"lead_sponsor_name":"The Affiliated Hospital of Qingdao University","has_results":false},{"nct_id":"NCT07088354","title":"Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT05800197","title":"Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Blokhin's Russian Cancer Research Center","has_results":false},{"nct_id":"NCT07329920","title":"Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Guo ShiWei","has_results":false},{"nct_id":"NCT04408859","title":"Quality of Life in Advanced Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy","phase":"","overall_status":"UNKNOWN","enrollment_count":290,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}